Connect with us

COVID-19

Us Authorizes J&J Covid Vaccine For Emergency Use

Published

on

Us Authorizes J&J Covid Vaccine For Emergency Use

The United States on Saturday authorized Johnson & Johnson’s Covid vaccine, otherwise known as J&J COVID Vaccine for emergency use, giving the nation a third shot to battle the outbreak that has killed more than 500,000 Americans.
The single-shot vaccine is highly effective in preventing severe Covid-19, including against newer variants, the Food and Drug Administration (FDA) said before giving it a green light.
He urged Americans to remain vigilant with anti-virus curbs such as social distancing, warning that new variants of the virus still posed a threat.

YOU CAN FOLLOW US ON FACEBOOK
A third vaccine is seen as a vital means to ramp up the immunization rate in the United States, where more than 500,000 people have lost their lives to the coronavirus.
In large clinical trials, the J&J vaccine’s efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.
Overall, among 39,321 participants across all regions, the efficacy against severe Covid-19 was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.
Crucially, analyses of various demographic groups revealed no marked differences across age, race, or people with underlying conditions.
The J&J vaccine is the third to be greenlighted in the United States after Pfizer’s and Moderna’s were provisionally approved in December.

Read Also: Osun Records Five Cases of UK’s COVID-19 Strain(Opens in a new browser tab)

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

COVID-19

U.S Approves Pfizer COVID Booster for The Elderly and High-Risk

Published

on

U.S Approves Pfizer COVID Booster for The Elderly and High-Risk

The U.S has authorised the administration of boosters of the Pfizer-Biontech Covid-19 vaccine for people aged over 65, as well as adults at high risk of severe disease and those in high-exposure jobs.

The announcement means a significant part of the US population – amounting to tens of millions of Americans – are now eligible for a third shot six months after their second.

The decision was expected and came after an independent expert panel convened by the regulatory agency last week voted in favour of recommending the move.

Watch Our Youtube Videos

The panel, however, rejected an initial plan by the white house to fully approve Pfizer boosters for everyone aged 16 and over, in what amounted to a rare rebuke of President Joe Biden’s administration.

Pfizer Covid-19 boosters are currently being debated by a separate body of experts convened by the centers for disease control and prevention, which may recommend further specifics about recipients of the vaccine.

Read Also:

President Biden Pledges 500m More Vaccine Doses to Developing World

Japan Detects More Moderna Vaccine Contamination

 

Continue Reading

COVID-19

India Resumes Export of Covid-19 Vaccine from October

Published

on

India Resumes Export of Covid-19 Vaccine from October

India will resume exporting Covid-19 vaccines from October, five months after it stopped sending supplies abroad in the face of a deadly wave of infections, the health minister said on Monday.

The world’s largest vaccine producer had halted exports in April, when a virus surge in India pushed the healthcare system to breaking point and there was a huge demand for jabs.

Health Minister Mansukh Mandaviya said more than 300 million vaccine doses would be produced in October and one billion in the last three months of the year.

Follow us on Facebook

“India will be resuming export of vaccines in order to fulfill the commitment of India towards Covax. The surplus supply of vaccines will be used to fulfill our commitment towards the world for the collective fight against Covid-19”, Mandaviya said in a statement.

India wants to vaccinate its adult population by the end of 2021. It has given more than 818 million doses of the three approved jabs since the beginning of the vaccination drive in January. On Friday, it administered a record-breaking 20 million doses, surpassing the country’s previous best daily tally of more than 13 million jabs on 27 August.

Read Also:

Court Orders Resident Doctors to Call Off Strike

AU Rolls Out 400m Vaccine Doses to Member States

Continue Reading

COVID-19

Pfizer Says Its Covid-19 Jab Safe for Children Aged 5-11

Published

on

Pfizer Says Its Covid-19 Jab Safe for Children Aged 5-11

Pfizer and Biontech on Monday said trial results showed their Coronavirus vaccine was safe and produced a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.

The vaccine would be administered at a lower dosage than for people over 12, they said.

They plan to submit their data to regulatory bodies in the European Union, the united states and around the world “as soon as possible”.

Follow us on Facebook

The trial results are the first of their kind for children under 12, with a Moderna trial for six-11-year-olds still ongoing.

Both the Pfizer and Moderna jabs are already being administered to adolescents over 12 and adults in countries around the globe.

Although children are considered less at risk of severe cases of Covid-19, there are concerns that the highly contagious delta variant could lead to more serious cases.

Inoculating children is also seen as key to keeping schools open and helping end the pandemic.

Read Also:

Nigerian Doctor Helps Pfizer Develop First Effective COVID-19 Vaccine

NPHCDA Begins Online Registration Of Nigerians For COVID-19 Vaccination

Continue Reading

Trending